| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OTLK | Common Stock | Other | -$3.13M | -2.5M | -9.81% | $1.25 | 23M | Feb 1, 2022 | See Footnote | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | These securities are held of record by BioLexis Pte Ltd. ("BioLexis") and represent the number securities in which Arun Kumar Pillai ("Kumar"), a natural person, may be deemed to have an indirect pecuniary interest in by virtue of the relationships described herein. Tenshi Life Sciences Private Limited and Tenshi Life Sciences Pte. Limited (collectively, "Tenshi"), both private investment vehicles controlled by Kumar, are beneficial owners of BioLexis and Kumar is the holder of a controlling interest in Tenshi. Kumar disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. |
| F2 | On January 31, 2022, GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, entered into a securities purchase agreement with each Tenshi entity, pursuant to which GMS Pharma purchased from Tenshi approximately 4.9% of the outstanding shares of BioLexis (the "Share Sale"), which corresponds to 2,500,000 shares of the Issuer held by BioLexis. The Share Sale closed on February 1, 2022. |
| F3 | BioLexis has designated one representative to serve on the Issuer's board of directors. This report shall not be deemed an admission that Kumar is the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |